IP Verse

Bispecific Antibodies Against Cd3Epsilon And Bcma For Use In Treatment Of Diseases - EP3227333B1

PatentPatent Analysis

EP3227333

BRISTOL MYERS SQUIBB
Application Number
EP15804458A
Filing Date
Dec 2, 2015
Status
Granted And Under Opposition
Jul 14, 2023
Grant Date
Aug 16, 2023
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3781132B1
EP3818078B1
EP3631454B1

Bibliography

The patent EP3227333B1 was granted to Bristol Myers Squibb on Aug 16, 2023 following the initial filing on Dec 2, 2015 under the application number EP15804458A . The current legal status of the patent is Granted And Under Opposition.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

PFIZERMay 16, 2024ADMISSIBLE
SCORPIOMay 16, 2024ADMISSIBLE
J A KEMPMay 14, 2024ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents